DelveInsight’s, “Acute Kidney Injury Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Acute Kidney Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Acute Kidney Injury pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Acute Kidney Injury NDA approvals (if any), and product development activities comprising the technology, Acute Kidney Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Acute Kidney Injury Pipeline Insight Report
To explore more information on the latest breakthroughs in the Acute Kidney Injury Pipeline treatment landscape of the report, click here @ Acute Kidney Injury Pipeline Outlook
Acute Kidney Injury Overview
Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in your blood and makes it hard for your kidneys to keep the right balance of fluid in your body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults. There are rarely any symptoms until the condition has progressed to a late stage. However, if there are symptoms, the most common one is a decrease in urine output.
Recent Developmental Activities in the Acute Kidney Injury Pipeline
Request a sample and discover the recent advances in Acute Kidney Injury Ongoing Clinical Trial Analysis and Medications, click here @ Acute Kidney Injury Treatment Landscape
Acute Kidney Injury Emerging Drugs Profile
RMC-035: GUARD THERAPEUTICS
Guard Therapeutics is developing RMC-035 (ROSgard), a biological drug candidate that utilizes one of the body’s most powerful and universal protections against oxidative stress. RMC-035 is naturally designed to “target” the kidneys, allowing RMC-035 to be present when the kidneys are attacked by oxidative stress. Treatment with RMC-035 has the potential to save lives and prevent the risk of both acute and chronic kidney damage with subsequent serious consequences due to impaired kidney function, such as life-sustaining dialysis treatment. Currently, it is in Phase II stage of clinical trial evaluation to treat Acute Kidney Injury.
RBT-1: Rénibus Therapeutics
Rénibus’ lead product, RBT-1, is a novel pharmacologic intervention combining stannous protoporphyrin and iron sucrose, induces a preconditioning protective effect on the kidney and other organs, upregulating production of protective proteins to prevent post-operative complications following cardiothoracic surgery, including AKI, days in the ICU, time on ventilator, and hospital readmission rates. Pre-clinical and Phase I development is complete, and RBT-1’s Phase II trial a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study) was initiated in April 2021 and is expected to be completed in Q4 2022. A pre-specified interim analysis was conducted following the enrollment of the first 60 patients, yielding statistically significant results in both the primary and several secondary endpoints.
Acute Kidney Injury Pipeline Therapeutics Analysis
There are approx. 30+ key companies which are developing the therapies for Acute Kidney Injury. The companies which have their Acute Kidney Injury drug candidates in the most advanced stage, i.e. phase II include, GUARD THERAPEUTICS.
For further information, refer to the detailed Acute Kidney Injury Unmet Needs, Acute Kidney Injury Market Drivers, and Market Barriers, click here for Acute Kidney Injury Ongoing Clinical Trial Analysis
Scope of the Acute Kidney Injury Pipeline Report
Dive deep into rich insights for drugs for Acute Kidney Injury Market Drivers and Acute Kidney Injury Market Barriers, click here @ Acute Kidney Injury Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Acute Kidney Injury Mergers and acquisitions, Acute Kidney Injury Licensing Activities @ Acute Kidney Injury Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services